SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 1454-1459

  Hubáček, Jaroslav A ^a   Dlouhá, Dana ^a   Adámková, Vera ^a   Zlatohlávek, Lukáš ^b   Viklický, Ondřej ^a   Hrubá, Petra ^a   Češka, Richard ^b   Vrablík, Michal ^b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Genetic; Hydroxymethylglutaryl CoA reductase Inhibitors; Muscular diseases; Polymorphism

Indexed keywords

ATORVASTATIN; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN;

AGED; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOPATHY; POLYMERASE CHAIN REACTION; BIOLOGICAL MODEL; CHEMICALLY INDUCED; CZECH REPUBLIC; DIABETES MELLITUS; DOSE RESPONSE; DYSLIPIDEMIAS; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; LIVER CELL; METABOLISM; MIDDLE AGED; MUSCULAR DISEASES; OBESITY; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

AGED; ATORVASTATIN CALCIUM; CZECH REPUBLIC; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MODELS, GENETIC; MUSCULAR DISEASES; MYALGIA; OBESITY; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIMVASTATIN; SMOKING;

EID: 84929504796     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.893007     Document Type: Article

References (26)

1. Mikhailidis DP, Athyros VG: Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat Rev Cardiol, 2014; 11: 72–74
2. Vrablik M, Zlatohlavek L, Stulc T et al: Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res, 2014; 63 (Suppl.3): S327–34
3. Stewart A: SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr, 2013; 5. pii: ecurrents.eogt.d21e7f0c58463571bb0d9d3a19b82203
4. Needham M, Mastaglia FL: Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord, 2014; 24: 4–15
5. SEARCH Collaborative Group, Link E, Parish S et al: SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med, 2008; 359: 789–99
6. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther, 2006; 80: 356–66
7. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics, 2006; 16: 873–79
8. Hubacek JA, Adamkova V, Lanska V et al: Variant within CELSR2/PSRC1/ SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. J Appl Biomed, 2012; 10: 19–28
9. Vrablík M, Hubáček JA, Dlouhá D et al: Impact of variants within seven candidate genes on statin treatment efficacy. Physiol Res, 2012; 61: 609–17
10. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther, 2007; 82: 726–33
11. Thunsdall-Pedoe H, Kuulasmaa K, Tolonen H et al: MONICA monograph and multimedia sourcebook. Thunsdall-Pedoe H (ed.), Geneva: World Health Organisation, 2003
12. Cífková R, Skodová Z, Bruthans J et al: Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/
13. Czech MONICA and Czech post-MONICA. Atherosclerosis, 2010; 211: 676–81
14. Hubacek JA, Dlouha D, Adámkova V et al: Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. Neuro Endocrinol Lett, 2012; 33(Suppl.2): 22–25
15. Santos PC, Soares RA, Nascimento RM et al: SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet, 2011; 12: 136
16. Hubacek JA: Drug metabolising enzyme polymorphisms in Middle- and Eastern-European Slavic populations. Drug Metabol Drug Interact, 2014; 29: 29–36
17. Pasanen MK, Neuvonen PJ, Niemi M: Global analysis of genetic variation in SLCO1B 1. Pharmacogenomics, 2008; 9: 19–33
18. Vrablík M, Freiberger T, Lánská V, Ceska R: [The Atractiv project: improvement of cardiovascular preventive in primary care in the Czech Republic.] Vnitr Lek, 2008; 54: 1131–39 [in Czech]
19. Danik JS, Chasman DI, MacFadyen JG et al: Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J, 2013; 165: 1008–14
20. Santos PC, Gagliardi AC, Miname MH et al: SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol, 2012; 68: 273–79
21. Donnelly LA, Doney AS, Tvendale R et al: Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther, 2011; 89: 210–16
22. Brunham LR, Lansberg PJ, Zhang L et al: Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J, 2012; 12: 233–37
23. de Keyser CE, Peters BJ, Becker ML et al: The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics, 2014; 24: 43–51
24. Voora D, Shah SH, Spasojevic I et al: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol, 2009; 54: 1609–16
25. Marciante KD, Durda JP, Heckbert SR et al: Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics, 2011; 21: 280–88
26. Talameh JA, Kitzmiller JP: Pharmacogenetics of statin-induced myopathy: A focused review of the clinical translation of pharmacokinetic genetic variants. J Pharmacogenomics Pharmacoproteomics, 2014; 5: 128